Skip Navigation

This Article
Right arrow Extract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Right arrow Request Permissions
Google Scholar
Right arrow Search for Related Content
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The European Society of Cardiology 2005. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Foreword

The PEGASUS (Pan-European Group on Acute St-elevation myocardial infarction, Urgent cardiac care, and Shock) Group is an independent group of European investigators focused on the field of mechanical reperfusion for acute myocardial infarction and acute critical care.

The primary aim of this free and open association is promoting original investigations and quick spread of new therapy advancements, as well as periodical updates on treatment of acute myocardial infarction and other acute coronary syndromes.

Founder members of this association are David Antoniucci (Italy), Edoardo Camenzind (Switzerland), Dariusz Dudek (Poland), Gilles Montalescot (France), and Franz-Joseph Neumann (Germany).

PEGASUS is the editor of this supplement of the EHJ that is the first official outing of the group. This supplement includes critical reviews of the efficacy of percutaneous intervention in terms of microvessel reperfusion, the pre-cath lab administration of IIb/IIIa inhibitors, the current role of thrombectomy and anti-embolic devices, and the interpretative problems related to the negative or conflicting results of randomized studies based on an empirical approach rather than a Bayesian approach to investigate the efficacy of a new treatment.

We hope this venture will meet the approval of cardiologists interested in this field.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?



This Article
Right arrow Extract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Right arrow Request Permissions
Google Scholar
Right arrow Search for Related Content
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?